250 related articles for article (PubMed ID: 35367648)
1. Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability.
Cleyle J; Hardy MP; Minati R; Courcelles M; Durette C; Lanoix J; Laverdure JP; Vincent K; Perreault C; Thibault P
Mol Cell Proteomics; 2022 May; 21(5):100228. PubMed ID: 35367648
[TBL] [Abstract][Full Text] [Related]
2. Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer.
Rospo G; Chilà R; Matafora V; Basso V; Lamba S; Bartolini A; Bachi A; Di Nicolantonio F; Mondino A; Germano G; Bardelli A
Genome Med; 2024 Jan; 16(1):15. PubMed ID: 38243308
[TBL] [Abstract][Full Text] [Related]
3. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel.
Park R; Saeed A
NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784
[TBL] [Abstract][Full Text] [Related]
5. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
6. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
7. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
[TBL] [Abstract][Full Text] [Related]
9. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
10. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
[TBL] [Abstract][Full Text] [Related]
11. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
13. Opportunities for immunotherapy in microsatellite instable colorectal cancer.
Westdorp H; Fennemann FL; Weren RD; Bisseling TM; Ligtenberg MJ; Figdor CG; Schreibelt G; Hoogerbrugge N; Wimmers F; de Vries IJ
Cancer Immunol Immunother; 2016 Oct; 65(10):1249-59. PubMed ID: 27060000
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
[TBL] [Abstract][Full Text] [Related]
16. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
18. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
19. Facts and Hopes in Colorectal Cancer Immunotherapy.
Foote MB; Argilés G; Rousseau B; Segal NH
Clin Cancer Res; 2023 Oct; 29(20):4032-4039. PubMed ID: 37326624
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses.
Zhao X; Yuan C; Wangmo D; Subramanian S
Gastroenterology; 2021 Aug; 161(2):560-574.e11. PubMed ID: 33895168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
